Women with ERα positive tumors are treated with drugs that either suppress the production of estrogen (aromatase inhibitors [AIs]), or block estrogen signaling (e.g. tamoxifen), in order to reduce the risk of breast cancer recurrence. This evidence concerns the gene ESR1 and breast cancer.